{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:27:58Z","timestamp":1781893678239,"version":"3.54.5"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.biopha.2023.115099","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T11:34:23Z","timestamp":1688124863000},"page":"115099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8188-9056","authenticated-orcid":false,"given":"Benjamin Ayodipupo","family":"Babalola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwamayowa Samuel","family":"Akinsuyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth Oreoluwa","family":"Folajimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folakemi","family":"Olujimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Adebisi","family":"Otunba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Chikere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibitayo Ajayi","family":"Adewumagun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tosin Emmanuel","family":"Adetobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115099_bib1","unstructured":"World Health Organization\u2014WHO (2022). Severe Acute Respiratory Syndrome (SARS). Available online: https:\/\/www.who.int\/health-topics\/severe-acute-respiratory-syndrome#tab=tab_1 (accessed on 13 July 2022)."},{"key":"10.1016\/j.biopha.2023.115099_bib2","unstructured":"Centers for Disease Control and Prevention\u2014CDC. SARS Basics Fact Sheet (2017). Available online: https:\/\/www.cdc.gov\/sars\/about\/fs-sars.html (accessed on 13 July 2022)."},{"key":"10.1016\/j.biopha.2023.115099_bib3","first-page":"6","article-title":"Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.biopha.2023.115099_bib4","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3390\/covid1040061","article-title":"Computational study of the therapeutic potential of novel heterocyclic derivatives against SARS-CoV-2","volume":"1","author":"Babalola","year":"2021","journal-title":"COVID"},{"issue":"10","key":"10.1016\/j.biopha.2023.115099_bib5","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.26538\/tjnpr\/v6i10.22","article-title":"In silico evaluation of the inhibitory potential of cymbopogonol from Cymbopogon citratus towards falcipain-2 (FP2) cysteine protease of plasmodium falciparum","volume":"6","author":"Adetobi","year":"2022","journal-title":"Trop. J. Nat. Prod."},{"issue":"4","key":"10.1016\/j.biopha.2023.115099_bib6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3390\/covid1040061","article-title":"Computational study of the therapeutic potential of novel heterocyclic derivatives against SARS-CoV-2","volume":"1","author":"Babalola","year":"2021","journal-title":"COVID"},{"key":"10.1016\/j.biopha.2023.115099_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","article-title":"COVID-19: immunopathology and its implications for therapy","volume":"20","author":"Cao","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2023.115099_bib8","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.3390\/jcm11133838","article-title":"Current effective therapeutics in management of COVID-19","volume":"11","author":"Atluri","year":"2022","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.biopha.2023.115099_bib9","first-page":"102","article-title":"Mechanism and adverse effects of COVID-19 drugs: a basic review","volume":"13","author":"Zadeh","year":"2021","journal-title":"International Journal of Physiology, Pathophysiol. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115099_bib10","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivirand chloroquine effectively inhibit the recently emerged novelcoronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"10","key":"10.1016\/j.biopha.2023.115099_bib11","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/cid\/ciab698","article-title":"Remdesivir and mortality in patients with coronavirus disease 2019","volume":"74","author":"Diaz","year":"2022","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.biopha.2023.115099_bib12","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.biopha.2023.115099_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110532","article-title":"Safety profile of the antiviral drug remdesivir: an update","volume":"130","author":"Fan","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2023.115099_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jmii.2020.09.002","article-title":"Remdesivir use in the coronavirus disease 2019 pandemic: a mini-review","volume":"54","author":"Yang","year":"2021","journal-title":"J. Microbiol., Immunol. Infect."},{"key":"10.1016\/j.biopha.2023.115099_bib15","article-title":"Extraction, purification and characterization of papain cysteine-proteases from the leaves of carica papaya","volume":"19","author":"Babalola","year":"2023","journal-title":"Sci. Afr."},{"issue":"12","key":"10.1016\/j.biopha.2023.115099_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e08536","article-title":"Genomic, biochemical and microbial evaluation of probiotic potentials of bacterial isolates from fermented sorghum products","volume":"7","author":"Otunba","year":"2021","journal-title":"Heliyon"},{"issue":"36","key":"10.1016\/j.biopha.2023.115099_bib17","article-title":"Characterization of novel bacteriocin PB2 and comprehensive detection of the pediocin gene ped-A1 from Pediococcus pentosaceus PB2 strain isolated from a sorghum-based fermented beverage in Nigeria","volume":"1","author":"Otunba","year":"2022","journal-title":"Biotechnol. Rep."},{"key":"10.1016\/j.biopha.2023.115099_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1154296","article-title":"XBB. 1.5: A new threatening SARS-CoV-2 Omicron subvariant","volume":"14","author":"Islam","year":"2023","journal-title":"Frontiers in Microbiology"},{"key":"10.1016\/j.biopha.2023.115099_bib19","series-title":"Drug efflux pumps in cancer resistance pathways: from molecular recognition and characterization to possible inhibition strategies in chemotherapy","first-page":"1","article-title":"Efflux transporters in cancer resistance: molecular and functional characterization of P-glycoprotein","author":"Turner","year":"2020"},{"issue":"1","key":"10.1016\/j.biopha.2023.115099_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/j.biopha.2023.115099_bib21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fphar.2019.00305","article-title":"Antisense oligonucleotide: basic concepts and therapeutic application in inflammatory bowel disease","volume":"10","author":"Di Fusco","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2023.115099_bib22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.14304\/SURYA.JPR.V4N7.5","article-title":"RNA therapeutics: RNAi and antisense mechanisms and clinical applications","volume":"4","author":"Chery","year":"2016","journal-title":"Postdoc journal: a journal of postdoctoral research and postdoctoral affairs"},{"issue":"2","key":"10.1016\/j.biopha.2023.115099_bib23","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/molecules27020536","article-title":"Small drugs, huge impact: the extraordinary impact of antisense oligonucleotides in research and drug development","volume":"27","author":"Quemener","year":"2022","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.biopha.2023.115099_bib24","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000000323","article-title":"Antisense oligonucleotides: a primer","volume":"5","author":"Scoles","year":"2019","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.biopha.2023.115099_bib25","doi-asserted-by":"crossref","unstructured":"Li, Y., Garcia Jr, G., Arumugaswami, V. and Guo, F., 2021. Structure-based design of antisense oligonucleotides that inhibit SARS-CoV-2 replication. bioRxiv.","DOI":"10.1101\/2021.08.23.457434"},{"key":"10.1016\/j.biopha.2023.115099_bib26","article-title":"Translational control of covid-19 and its therapeutic implication","volume":"13","author":"Zhang","year":"2022","journal-title":"Frontiers in immunology"},{"key":"10.1016\/j.biopha.2023.115099_bib27","unstructured":"Lulla, V., Wandel, M.P., Bandyra, K.J., Dendooven, T., Yang, X., Doyle, N., Oerum, S., Randow, F., Maier, H.J., Scott, W. and Ding, Y., 2020. Antisense oligonucleotides target a nearly invariant structural element from the SARS-CoV-2 genome and drive RNA degradation."},{"issue":"21","key":"10.1016\/j.biopha.2023.115099_bib28","doi-asserted-by":"crossref","first-page":"12502","DOI":"10.1093\/nar\/gkab1096","article-title":"Inhibition of SARS-CoV-2 coronavirus proliferation by designer antisense-circRNAs","volume":"49","author":"Pfafenrot","year":"2021","journal-title":"Nucleic Acids Res."},{"issue":"40","key":"10.1016\/j.biopha.2023.115099_bib29","doi-asserted-by":"crossref","first-page":"21830","DOI":"10.1002\/ange.202105942","article-title":"Efficient Inhibition of SARS\u2010CoV\u20102 Using Chimeric Antisense Oligonucleotides through RNase L Activation","volume":"133","author":"Su","year":"2021","journal-title":"Angewandte Chemie"},{"issue":"1","key":"10.1016\/j.biopha.2023.115099_bib30","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1038\/s41467-022-32216-0","article-title":"An intranasal ASO therapeutic targeting SARS-CoV-2","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.115099_bib31","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/pathogens11111286","article-title":"Antiviral activity of oligonucleotides targeting the SARS-CoV-2 genomic RNA stem-loop sequences within the 3\u2032-End of the ORF1b","volume":"no. 11","author":"Stincarelli","year":"2022","journal-title":"Pathogens 11"},{"issue":"3","key":"10.1016\/j.biopha.2023.115099_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/nat.2020.0868","article-title":"Oligonucleotides and the COVID-19 pandemic: a perspective","volume":"30","author":"Rossi","year":"2020","journal-title":"nucleic acid therapeutics"},{"issue":"5","key":"10.1016\/j.biopha.2023.115099_bib33","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.tibs.2020.11.010","article-title":"Nucleic acid-based technologies targeting coronaviruses","volume":"46","author":"Le","year":"2021","journal-title":"Trends in Biochemical Sciences"},{"issue":"5","key":"10.1016\/j.biopha.2023.115099_bib34","first-page":"347","article-title":"Antisense oligonucleotides: basic concepts and mechanisms","volume":"1","author":"Dias","year":"2002","journal-title":"Molecular cancer therapeutics"},{"issue":"5","key":"10.1016\/j.biopha.2023.115099_bib35","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/nar\/29.5.1034","article-title":"Statistical prediction of single-stranded regions in RNA secondary structure and application to predicting effective antisense target sites and beyond","volume":"29","author":"Ding","year":"2001","journal-title":"Nucleic acids research"},{"issue":"6","key":"10.1016\/j.biopha.2023.115099_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128686","article-title":"RNA interference-guided targeting of hepatitis C virus replication with antisense locked nucleic acid-based oligonucleotides containing 8-oxo-dG modifications","volume":"10","author":"Mutso","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.115099_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2021.101003","article-title":"From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases","volume":"81","author":"Pandey","year":"2021","journal-title":"Molecular Aspects of Medicine"},{"issue":"1","key":"10.1016\/j.biopha.2023.115099_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/rr32","article-title":"Respirable antisense oligonucleotides: a new drug class for respiratory disease","volume":"2","author":"Tanaka","year":"2000","journal-title":"Respiratory Research"},{"key":"10.1016\/j.biopha.2023.115099_bib39","unstructured":"Thorpe, C., 2021. Synthesis, structure and application of backbone modified nucleic acids (Doctoral dissertation, University of Oxford)."},{"key":"10.1016\/j.biopha.2023.115099_bib40","unstructured":"Stein, D., Skilling, D., Iversen, O., Smith, A. 2003 Antisense antiviral agent and method for treating ssRNA viral infection. Google Patents. https:\/\/patents.google.com\/patent\/US20030224353A1\/en."},{"key":"10.1016\/j.biopha.2023.115099_bib41","unstructured":"Ionis Pharmaceutical (2005) Composition and methods for the treatment of SARS. https:\/\/patentimages.storage.googleapis.com\/b1\/26\/0a\/5ba806014c3fe0\/WO2005023083A2.pdf."},{"key":"10.1016\/j.biopha.2023.115099_bib42","unstructured":"Iversen, P.L. (2005). Sense antiviral compound and ethid for treating ssRNA viral infection. https:\/\/patentimages.storage.googleapis.com\/7f\/5d\/c4\/bb8295b9408407\/WO2005013905A2.pdf."},{"issue":"6","key":"10.1016\/j.biopha.2023.115099_bib43","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.biopha.2023.115099_bib44","doi-asserted-by":"crossref","first-page":"9939","DOI":"10.1007\/s11033-020-05988-1","article-title":"Potential approaches to combat COVID-19: a mini-review","volume":"47","author":"Zainab","year":"2020","journal-title":"Mol. Biol. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2023.115099_bib45","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1084\/jem.161.2.378","article-title":"Successful treatment of autoimmunity in NZB\/NZW F1 mice with monoclonal antibody to L3T4","volume":"161","author":"Wofsy","year":"1985","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.biopha.2023.115099_bib46","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/bjc.2015.163","article-title":"Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells","volume":"112","author":"Caiazza","year":"2015","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.biopha.2023.115099_bib47","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/nm.2236","article-title":"Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance","volume":"16","author":"Tanaka","year":"2010","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.biopha.2023.115099_bib48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1535-7163.MCT-11-0508","article-title":"A monoclonal antibody against human Notch1 ligand\u2013binding domain depletes subpopulation of putative breast cancer stem\u2013like cells","volume":"11","author":"Sharma","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2023.115099_bib49","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/14737175.2017.1245616","article-title":"Anti-CD20 monoclonal antibodies in multiple sclerosis","volume":"4","author":"Moreno Torres","year":"2017","journal-title":"Expert Rev. Neurother. 17"},{"issue":"9","key":"10.1016\/j.biopha.2023.115099_bib50","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1586\/14737175.2014.945522","article-title":"Efficacy and safety studies of gantenerumab in patients with Alzheimer\u2019s disease","volume":"14","author":"Panza","year":"2014","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.biopha.2023.115099_bib51","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","article-title":"Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.115099_bib52","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.115099_bib53","first-page":"423","article-title":"Monoclonal antibody therapy in COVID-19","volume":"35","author":"Conti","year":"2021","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.biopha.2023.115099_bib54","unstructured":"Bamlanivimab (LY-Cov555) for the Treatment of COVID-19, USA. Available at: https:\/\/www. clinicaltrialsarena.com\/projects\/bamlanivimab-ly-cov555-for-the-treatment-of-covid-19\/. Accessed on 1 March 2020."},{"key":"10.1016\/j.biopha.2023.115099_bib55","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"BLAZE-1 investigators. bam-lanivimab plus etesevimab in mild or moderate COVID-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.biopha.2023.115099_bib56","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2023.115099_bib57","first-page":"238","article-title":"The COVID-19 phase 3 prevention trial team. Subcutaneous REGEN-COV antibody combination to prevent COVID-19: August 4, 2021","volume":"384","author":"O\u2019Brien","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115099_bib59","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1038\/s41551-020-00660-2","article-title":"Neutralizing antibodies for the treatment of COVID-19","volume":"4","author":"Jiang","year":"2020","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.biopha.2023.115099_bib60","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bj.2020.11.011","article-title":"Neutralizing monoclonal antibodies for COVID-19 treatment and prevention","volume":"44","author":"Jaworski","year":"2021","journal-title":"biomedical journal"},{"key":"10.1016\/j.biopha.2023.115099_bib61","doi-asserted-by":"crossref","first-page":"2293e303","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115099_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.115099_bib63","article-title":"SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19","author":"Chen","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2023.115099_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS- CoV-2 infection in non-human primates","author":"Jones","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2023.115099_bib65","unstructured":"US Food and Drug Administration, 2020. Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab. FDA https:\/\/www.fda.gov\/ media\/143603\/download."},{"issue":"6","key":"10.1016\/j.biopha.2023.115099_bib66","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2023.115099_bib67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 suppresses viremia in HIV-1-infected individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat. Med."},{"issue":"7724","key":"10.1016\/j.biopha.2023.115099_bib68","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.115099_bib69","doi-asserted-by":"crossref","DOI":"10.18203\/2319-2003.ijbcp20213645","article-title":"Monoclonal antibodies in COVID-19 management: a scoping review","author":"Adaikkalavan","year":"2021","journal-title":"Int. J. Basic Clin. Pharm."},{"key":"10.1016\/j.biopha.2023.115099_bib70","first-page":"9","volume":"325","year":"2021","journal-title":"An EUA for Bamlanivimab\u2014AMonoclonal Antibody for COVID-19 Clinical Review & Education"},{"key":"10.1016\/j.biopha.2023.115099_bib71","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2023.115099_bib72","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.115099_bib73","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.115099_bib74","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.115099_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155627","article-title":"Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: a pilot study","volume":"146","author":"Avdeev","year":"2021","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.biopha.2023.115099_bib76","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3390\/v13061171","article-title":"Anti-SARS-CoV-2 vaccines and monoclonal antibodies facing viral variants","volume":"13","author":"Chaqroun","year":"2021","journal-title":"Viruses"},{"issue":"10","key":"10.1016\/j.biopha.2023.115099_bib77","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1038\/s41423-021-00752-2","article-title":"Neutralizing antibodies for the prevention and treatment of COVID-19","volume":"18","author":"Du","year":"2021","journal-title":"Cellular & molecular immunology"},{"key":"10.1016\/j.biopha.2023.115099_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2022.114819","article-title":"Hybrid CRISPR\/Cas protein for one-pot detection of DNA and RNA","volume":"219","author":"Guk","year":"2023","journal-title":"Biosensors and Bioelectronics"},{"key":"10.1016\/j.biopha.2023.115099_bib79","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1038\/srep10833","article-title":"CRISPR\/Cas9 cleavage QWG of viral DNA efficiently suppresses hepatitis B virus","volume":"5","author":"Ramanan","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.115099_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2020.03.005","article-title":"Permanent inactivation of HBV genomes by CRISPR\/Cas9-mediated non-cleavage base editing","volume":"20","author":"Yang","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2023.115099_bib81","doi-asserted-by":"crossref","first-page":"41968","DOI":"10.1038\/srep41968","article-title":"A combinational CRISPR\/Cas9 gene-editing approach can halt HIV replication and prevent viral escape","volume":"7","author":"Lebbink","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.115099_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-10366-y","article-title":"Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice","volume":"10","author":"Dash","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.115099_bib83","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1099\/vir.0.000139","article-title":"Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR\/Cas9","volume":"96","author":"Li","year":"2015","journal-title":"JGen Virol."},{"key":"10.1016\/j.biopha.2023.115099_bib84","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.virusres.2017.04.019","article-title":"Suppression of Epstein-Barr virus DNA load in latently infected nasopharyngeal carcinoma cells by CRISPR\/Cas9","volume":"244","author":"Yuen","year":"2018","journal-title":"Virus Res."},{"key":"10.1016\/j.biopha.2023.115099_bib85","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/612823","article-title":"Disruption of HPV16-E7 by CRISPR\/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells","author":"Hu","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.biopha.2023.115099_bib86","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41422-020-0290-0","article-title":"Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses","volume":"30","author":"Nguyen","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.biopha.2023.115099_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02355-3","article-title":"SARS-CoV-2 RNA polymerase as target for antiviral therapy","volume":"18","author":"Buonaguro","year":"2020","journal-title":"Journal of Translational Medicine"},{"issue":"6","key":"10.1016\/j.biopha.2023.115099_bib88","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41587-021-00822-w","article-title":"Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents","volume":"39","author":"Blanchard","year":"2021","journal-title":"Nature biotechnology"},{"issue":"10","key":"10.1016\/j.biopha.2023.115099_fur1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.tim.2021.07.002","article-title":"Molecular determinants of SARS-CoV-2 variants","volume":"29","author":"Banerjee","year":"2021","journal-title":"Trends in Microbiology"},{"issue":"7764","key":"10.1016\/j.biopha.2023.115099_fur2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/d41586-019-02087-5","article-title":"Hijacking evolution","volume":"571","author":"Scudellari","year":"2019","journal-title":"Nature"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223008909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223008909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:09:26Z","timestamp":1777878566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223008909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":89,"alternative-id":["S0753332223008909"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115099","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115099"}}